Jump Power Peaks in Early Adulthood, Then Gradually Falls

Key Takeaways

• In 30,217 Finns aged 6-75, countermovement jump height and estimated peak power increased through childhood and adolescence, then declined with age.
• By mean values, males peaked for jump height at 16-20 and peak power at 21-25; females peaked for both at 21-25.
• Segmented regression suggested somewhat earlier peak ages: 18 and 21 in males, 17 and 19 in females for jump height and peak power respectively.
• From ages 11-15, males showed larger annual gains in jump height than females; after peak, declines were modest at roughly 0.9% per year for jump height and 0.3%-0.7% for peak power over ages 52-58.
• This was an observational, pooled dataset study using contact-mat jumps and estimated power equations, so it describes patterns across age and sex rather than testing causes or supplements.
• For creatine users, the practical message is to pair proven dosing with resistance and power training, especially during late adolescence, early adulthood and older age when preserving power matters.

What the study found about power across the lifespan

This new paper pooled data from five Finnish datasets to map how lower-extremity power changes from childhood to older adulthood. Using countermovement jump (CMJ) height and estimated peak power, the researchers analysed 30,217 participants aged 6 to 75 years: 24,804 males and 5,413 females.

The big picture was straightforward. Jump height and estimated peak power rose through childhood and adolescence, peaked in late adolescence or early adulthood, and then gradually declined. The timing of that peak differed somewhat by sex and by the metric used.

• Males: mean CMJ height peaked at ages 16-20, while mean peak power peaked at 21-25.
• Females: both mean CMJ height and mean peak power peaked at 21-25.
• Segmented regression: peak ages appeared slightly earlier, at 18 and 21 in males and 17 and 19 in females for CMJ height and peak power respectively.

The study also highlighted the adolescent divergence between sexes. From ages 11 to 15, males showed greater annual relative gains in CMJ height than females: 5.6% versus 3.1%. For peak power, yearly gains over that span ranged from 4.7% to 7.6% in males and 4.0% to 7.3% in females, depending on the power expression used.

After peak, the decline was gradual rather than dramatic. Over ages 52-58, annual declines were about 0.9% for CMJ height and roughly 0.3% to 0.7% for peak power in both sexes. That matters because power is one of the physical qualities most closely tied to athletic explosiveness and, later in life, everyday function.

How the research was done and what its limits are

This was a large observational analysis, not a supplementation trial. The researchers combined five Finnish datasets and grouped participants into five-year age bands to compare average performance. CMJ height was measured on a contact mat using flight time, and peak power was estimated with equations developed for adults and children. Power was also expressed relative to body mass in watts per kilogram.

That design gives the paper a major strength: scale. More than 30,000 participants across ages 6 to 75 provides a broad picture of how jump performance tends to change across the lifespan. It also addresses an area where data are often patchy, especially in the transition from late adolescence to early adulthood.

But readers should be careful about what the study can and cannot say.

• It shows age- and sex-related patterns, not causes.
• Because the data were pooled from multiple datasets, there may be differences in participant background, training status or testing context.
• Peak power was estimated from equations rather than measured directly with force plates.
• The sample was heavily skewed toward males, which can affect precision when comparing sexes.
• The paper does not test diet, creatine use, resistance training history or other factors that may influence power.

So this is best understood as a normative map of jumping performance, not proof that any one intervention changes the age curve. That distinction matters for creatine: you cannot infer from this paper alone that creatine shifts peak age, slows decline, or works differently in men versus women. It simply identifies when lower-body power tends to be highest and when it starts to fade.

What it means in practice for people who take creatine

For creatine users, the practical value of this study is contextual rather than mechanistic. It helps identify when power is developing fastest, when it is typically highest, and when preserving it becomes more urgent. Creatine fits into that picture because it is one of the best-studied supplements for supporting high-intensity performance and training adaptations, especially when paired with structured exercise.

If your goal is lower-body power, the basics still apply:

• Use creatine monohydrate, the most-studied form. If you want help comparing options, see our best creatine rankings and creatine brand reviews.
• Maintenance dosing: 3-5 g per day is the standard evidence-based range.
• Optional loading: about 20 g per day, split into 4 doses, for 5-7 days can saturate muscle stores faster, followed by maintenance.
• Pair it with training: resistance exercise, sprint work and jump training are what directly target power.

This age-curve paper suggests three groups may be especially interested in that combination. First, younger athletes in adolescence and early adulthood, when power is rising or near its peak. Second, adult recreational lifters and team-sport athletes trying to maintain explosiveness. Third, older adults, for whom even modest losses in power can matter for performance and function.

If you are unsure how much to take, use our creatine dosage calculator. And if you are new to supplementation, our creatine guides explain dosing, timing and form selection in more detail. This study does not change creatine dosing, but it does reinforce why power is a worthwhile target across the lifespan.

How this fits with the broader creatine evidence

This Finnish paper is not about supplementation, but it slots neatly into an established sports-nutrition point: muscle power is highly trainable, highly relevant, and worth protecting as we age. Creatine matters here because the broader evidence base supports its use for repeated high-intensity exercise and for augmenting gains from resistance training.

The ISSN position stand remains one of the most useful summaries of that evidence. It concludes that creatine monohydrate is the most effective nutritional supplement currently available for increasing high-intensity exercise capacity and lean mass during training. A later review on common questions and misconceptions about creatine also reinforces that monohydrate is the reference form and that many common fears around healthy users are overstated.

What those papers do not say is also important. Creatine is not a substitute for training, and it is not a guarantee of better jump performance in every individual or every context. Effects can depend on baseline muscle creatine stores, training quality, body size, sport demands and the outcome being measured.

Still, if a new observational study tells us that lower-body power peaks in early adulthood and then slowly declines, the existing creatine literature helps translate that into action: maintain training quality, preserve muscle function, and use an evidence-based supplement if it supports your goals. For readers browsing products, our creatine product catalog can help narrow the field to plain, well-dosed monohydrate options.

Who should care most about these findings

Not every reader needs to react to this study in the same way. The practical significance depends on where you are on the age curve and what kind of performance you care about.

The main nuance is that this paper describes averages, not destiny. Some people will peak earlier, some later, and training status likely explains a lot of the variation. If you already supplement with creatine, this study is less a reason to change your dose than a reminder to stay focused on the performance quality that often slips first: power.

Bottom line for creatine users

This large Finnish study found that countermovement jump performance and estimated lower-body peak power generally rise through youth, peak in late adolescence or early adulthood, and then decline gradually with age. That is the news.

What it means for creatine users is more modest but still useful. The paper does not test creatine, so it cannot tell us whether supplementation changes the age of peak power or the rate of decline. What it does do is spotlight lower-body power as a lifespan performance trait that deserves attention.

If your goal is to jump higher, sprint better, or stay explosive as you get older, the evidence-based playbook remains the same:

1. Train for strength and power consistently.
2. Use creatine monohydrate if you want a well-supported supplement.
3. Take 3-5 g daily, or use a short loading phase if faster saturation matters.
4. Judge results over weeks of training, not days.

In short, this study provides a better map of when human jump power tends to peak and how slowly it fades. The broader creatine literature tells you what to do with that information: support the training that builds or preserves power, especially once age starts nudging it downward.

Power across the lifespan and the creatine basics

• 30,217 Total participants analysed — Finnish pooled dataset, ages 6-75
• 16-25 Typical peak window for jump metrics — Varied by sex and whether CMJ height or peak power was used
• 0.3%-0.9% Annual decline after peak — Approximate yearly drop over ages 52-58 depending on metric
• 3-5 g/day Standard creatine maintenance dose — Creatine monohydrate is the most-studied form

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN